Be sure to check our sister interview main ratings news website

Shield Therapeutics positioned for profitability with Viatris deal and its additional capital (VIDEO)

Shield Therapeutics (LON:STX) is the topic of conversation when Dr Martin Hall joins DirectorsTalk Interviews.

Martin summarises a number of announcements made by the company recently, explains Accrufer has performed in the US, a co-promotion deal with Viatris, changes made to the forecast and with the share price languishing what Martin expects to happen from here.

Shield Therapeutics plc is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead medicine ACCRUFeR.

Read in Full
Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    Hardman & Co

    More articles like this

    Hardman & Co

    Shield Therapeutics: Positioned for growth and profitability

    13th January 2023

    Shield Therapeutics plc (LON:STX) is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in July 2021, Shield has been

    Hardman & Co

    Shield Therapeutics: Accrufer momentum building

    16th September 2022

    Shield Therapeutics plc (LON:STX) is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Following launch of Accrufer® in the US, in July 2021, the

    Hardman & Co

    Shield Therapeutics: PBMs have bought in to Accrufer

    4th March 2022

    Shield Therapeutics plc (LON:STX) is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Following the US launch of Accrufer® in July 2021, the

    Hardman & Co

    Shield Therapeutics: Focused on US market penetration

    23rd August 2021

    Shield Therapeutics plc (LON:STX) is a commercial-stage pharmaceutical company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency (ID). Accrufer® has just been launched in the US by

    Hardman & Co

    Shield Therapeutics: Accrufer® launch on schedule

    26th May 2021

    Shield Therapeutics plc (LON:STX) is a commercial-stage pharmaceutical company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency (ID). Feraccru®/Accrufer® has been approved by the regulators in both

    Hardman & Co

    Shield Therapeutics US market offers a significant opportunity

    14th January 2021

    Shield Therapeutics plc (LON:STX) is the topic of conversation when Dr Martin Hall Analyst at Hardman & Co joins DirectorsTalk. Martin talks us through the company’s underperformance, explains how he thinks the shares could recover, how returns

    Hardman & Co

    Shield Therapeutics: Reassessing the US opportunity

    6th January 2021

    Shield Therapeutics plc (LON:STX) is a commercial-stage company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency (ID). Feraccru®/Accrufer® has been approved by the regulators in both Europe

    Hardman & Co

    Shield Therapeutics: Optimism over US deal

    21st September 2020

    Shield Therapeutics plc (LON:STX) is a commercial-stage company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency (ID). Feraccru/Accrufer has been approved by the regulators in both Europe

    Hardman & Co

    Shield Therapeutics Plc Good demand for Feraccru in Europe

    28th January 2020

    Shield Therapeutics (LON:STX) is a commercial-stage company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency (ID) with ferric maltol. Recent news that the FDA had approved this

    © 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.